Pharvaris (NASDAQ:PHVS) Sets New 12-Month High – What’s Next?

Pharvaris N.V. (NASDAQ:PHVS) shares hit a new 52-week high on Friday . The company traded as high as $37.14 and last traded at $35.8250, with a volume of 452 shares changing hands. The stock had previously closed at $34.45.

Analyst Ratings Changes

Several research firms recently commented on PHVS. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Wells Fargo & Company assumed coverage on shares of Pharvaris in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 price objective on the stock. Citizens Jmp decreased their target price on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Wall Street Zen cut shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Wolfe Research initiated coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.08.

Pharvaris Stock Up 2.0%

The company’s 50-day simple moving average is $33.14 and its 200 day simple moving average is $29.78. The company has a market capitalization of $2.30 billion, a P/E ratio of -11.00 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, equities research analysts forecast that Pharvaris N.V. will post -2.97 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Berndt Modig sold 2,291 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $31.07, for a total transaction of $71,181.37. Following the completion of the sale, the chief executive officer directly owned 135,209 shares of the company’s stock, valued at approximately $4,200,943.63. This represents a 1.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the transaction, the director owned 315,167 shares in the company, valued at $11,185,276.83. The trade was a 8.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 178,322 shares of company stock valued at $5,969,286. 11.84% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pharvaris

Hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in shares of Pharvaris in the fourth quarter worth about $35,000. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the last quarter. Barclays PLC bought a new stake in Pharvaris during the 4th quarter valued at approximately $77,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Pharvaris during the 4th quarter valued at approximately $86,000. Finally, CoreCap Advisors LLC acquired a new stake in Pharvaris in the 2nd quarter valued at approximately $93,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.